NCT00290251 2024-07-15
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
16 trialsNCT02425878 2020-10-14
Ulipristal Acetate 10 mg and Asisted Reproduction
Instituto Valenciano de Infertilidad, IVI VALENCIA
Phase 3 Terminated
NCT04132349 2020-04-13
Ulipristal Acetate in Symptomatic Uterine Fibroid
Mỹ Đức Hospital
Phase 4 Terminated
NCT02825719 2020-04-09
Ulipristal Use in Chinese Population
Queen Mary Hospital, Hong Kong
Phase 4 Terminated
NCT01629563 2019-09-04
PEARLIV
PregLem SA
Phase 3 Completed
NCT02147197 2019-04-30
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Allergan
Phase 3 Completed
NCT02357563 2016-11-18
Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation
University Magna Graecia
Phase 4 Unknown
NCT02361879 2016-11-18
Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma
University Magna Graecia
Phase 4 Unknown
NCT02361892 2016-11-18
UPA_ovAge
University Magna Graecia
Phase 4 Unknown
NCT02361905 2016-11-18
Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas
University Magna Graecia
Phase 4 Unknown
NCT02288130 2016-11-03
MYOMEX
Amsterdam UMC, location VUmc
Phase 4 Unknown
NCT02601196 2016-07-12
IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure
Sheba Medical Center
Phase 4 Unknown
NCT02440750 2016-03-09
Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women
University of Cagliari
Phase 4 Unknown
NCT01156857 2016-01-15
PEARLIII
PregLem SA
Phase 3 Completed
NCT01252069 2016-01-13
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)
PregLem SA
Phase 3 Completed
NCT01553123 2013-02-07
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
Watson Pharmaceuticals
Phase 3 Withdrawn